Cancer Nanomedicines in an Evolving Oncology Landscape

Peng Guo,Jing Huang,Marsha A Moses,Marsha A. Moses
DOI: https://doi.org/10.1016/j.tips.2020.08.001
IF: 17.638
2020-10-01
Trends in Pharmacological Sciences
Abstract:Nanomedicine represents an important class of cancer therapy. Clinical translation of cancer nanomedicine has significantly reduced the toxicity and adverse consequences of standard-of-care chemotherapy. Recent advances in new cancer treatment modalities (e.g., gene and immune therapies) are profoundly changing the oncology landscape, bringing with them new requirements and challenges for next-generation cancer nanomedicines. We present an overview of cancer nanomedicines in four emerging oncology-associated fields: (i) gene therapy, (ii) immunotherapy, (iii) extracellular vesicle (EV) therapy, and (iv) machine learning-assisted therapy. We discuss the incorporation of nanomedicine into these emerging disciplines, present prominent examples, and evaluate their advantages and challenges. Finally, we discuss future opportunities for next-generation cancer nanomedicines.
pharmacology & pharmacy
What problem does this paper attempt to address?